Selling Tobacco to Minors
Selling tobacco to those under 18 is illegal across the U.S., and some areas have set even higher age limits. However, a study conducted in a suburban county outside Denver and published Aug. 20 in JAMA Pediatrics indicates that it’s not unusual for retailers to sell tobacco to minors. The researchers had teens visit 201 stores—including convenience stores, liquor stores, grocery stores, pharmacies, tobacco stores and gas stations—and attempt to buy cigarettes. Each store in the study received six visits. More than half of the retailers sold cigarettes to minors at least once. On average per round of visits, 18 percent of stores violated the law.
When a Parent Has Cancer
A Danish study published Aug. 20 in the Journal of Epidemiology & Community Health shows the effect a parent’s cancer diagnosis can have on a child. Looking at a series of national registries, the researchers found that having a parent diagnosed with cancer during childhood was associated with reduced educational attainment and income at age 30. Children who were younger than age 5 when their parents were diagnosed or whose parents had a poor prognosis or died seemed to be particularly affected. The researchers say that their study points to a need for more resources to help children whose parents have cancer.
Mammograms After Breast Cancer
Breast cancer survivors who have not had a double mastectomy are recommended to get annual mammograms. A paper published Aug. 22 in JAMA Surgery indicates that changing recommendations for mammography for women in the general population may have inadvertently affected the treatment of breast cancer survivors. The researchers looked at insurance claims from Blue Cross Blue Shield of Michigan. They found that between 2008-2009 and 2012-2013, use of screening mammograms decreased in women in their 40s, especially in breast cancer survivors. The U.S. Preventive Services Task Force in 2009 released new breast cancer screening guidelines with reduced support for screening women in the general population in their 40s.
Immunotherapy vs. Melanoma Brain Metastases
Evidence continues to accumulate that checkpoint inhibitors, a form of immunotherapy drug, can help treat brain metastases in melanoma patients. The latest data are presented in a paper published Aug. 23 in the New England Journal of Medicine, which shows that a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) can in some cases lead brain metastases to recede. A story published in The New York Times points out that fewer than 20 percent of patients with melanoma live a year after presenting with brain metastases. Among patients who received the immunotherapy combination, 82 percent lived more than a year. First author of the study Hussein A. Tawbi of MD Anderson Cancer Center in Houston told the Times that the treatment should also be studied in patients with other tumor types with brain metastases.
Cancer Today magazine is free to cancer patients, survivors and caregivers who live in the U.S. Subscribe here to receive four issues per year.